A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 5, 2009, Pages 851-857

  Brell, Joanna M ^a,b   Krishnamurthi, Smitha S ^a,b   Javle, Milind ^c   Saltzman, Joel ^d   Wollner, Ira ^e   Pelley, Robert ^f   Dowlati, Afshin ^a,b   Kantharaj, Belagodu N ^g   Schluchter, Mark D ^a   Rath, Linda ^a,b   Ivy, S Percy ^h   Remick, Scot C ⁱ  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d Lake University   (United States)

^e HENRY FORD HEALTH SYSTEM   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g Community Health Partners ^*  (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Chemotherapy; Gastric cancer; Metastatic; Phase II

Indexed keywords

ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; CAPECITABINE; IRINOTECAN; OXALIPLATIN; PROCHLORPERAZINE; STEROID;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EMBOLISM; FATIGUE; FEMALE; GASTROESOPHAGEAL ADENOCARCINOMA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERKALEMIA; HYPOKALEMIA; LOWER ESOPHAGUS SPHINCTER; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; STOMACH CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PALLIATIVE CARE; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 61549123035     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0807-6     Document Type: Article

References (28)

1. SE Al-Batran A Atmaca S Hegewisch-Becker 2004 Phase II trial of biweekly infusional flurouracil, folinic acid, and oxaliplatin in patients with advanced gastric carcinoma J Clin Oncol 22 658 663
2. K Chansky J Benedetti JS Macdonald 2005 Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma Cancer 103 1165 1171
3. D Cunningham N Starling S Rao T Iveson M Nicolson F Coxon G Middleton F Daniel J Oates AR Norman Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom 2008 Capecitabine and oxaliplatin for advanced esophagogastric Cancer N Engl J Med 358 36 46
4. M Dank J Zaluski C Barone V Valvere C Peschel E Wenczl M Goker M Risse L Awad R Bugat 2005 Randomized phase 3 trial of irinotecan + 5FU/folinic acid vs CDDP + 5FU in first-line advanced gastric cancer patients J Clin Oncol 23 308s abstr 4003
5. SS Devesa WJ Blot JF Fraumeni Jr 1998 Changing patterns in the incidence of esophageal and gastric carcinoma in the United States Cancer 83 2049 2053
6. F DeVita M Orditura E Matano 2005 Phase II trial of biweekly oxaliplatin plus infusional 5-flurouracil and folinic acid (FOLFOX-4) as first-line therapy of advanced gastric carcinoma patients Br J Cancer 92 1644 1649
7. T Dragovich S McCoy CM Fenoglio-Preiser J Wang JK Benedetti AF Baker CB Hackett SG Urba KS Zaner CD Blanke JL Abbruzzese 2006 Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127 J Clin Oncol 24 4922 4927
8. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M (2002) AJCC Cancer staging manual, Chap. 10, 6th edn. Springer-Verlag, New York, p 112
9. P Hahnfeldt J Folkman L Hlatky 2003 Minimizing long-term tumor burden: logic for metronomic chemotherapeutic dosing and its angiogenesis basis J Theor Biol 220 545 554
10. A Jemel R Siegel E Ward T Murray J Xu MJ Thun 2007 Cancer statistics CA Cancer J Clin 57 43 66
11. G Keller H Hofler KF Becker 2005 Molecular medicine of gastric adenocarcinomas Expert Rev Mol Med 7 1 13 Review
12. Ni Kim YS Park DS Hedo C Suh SY Kim KC Park YK Kang DB Shin HT Kim HJ Kim 1993 Phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer Cancer 71 3813 3818
13. Krishnamurthi SS, Brell JM, Hoppel CL, Egorin MJ, Weaver KC, Li X, Ingalls ST, Zuhowski EG, Schluchter MD, Dowlati A, Cooney MM, Gibbons J, Overmoyer BA, Ivy SP, and Remick SC (2008) Phase I clinical trial and pharmacokinetic study of oxaliplatin, irinotecan, and capecitabine. Cancer Chemother Pharmacol Apr 15 [Epub ahead of print]
14. AJ Ocean F Schnoll-Sussman R Keresztes X Chen S Holloway N Matthews P Christos M Mazumdar J Wright S Wadler 2006 Phase II study of PS-341 (bortrezominb) with or withour irinotecan in patients with advanced gastric adenocarcinomas. ASCO annual meeting proceedings J Clin Oncol 24 14040
15. C Pinto F Di Fabio S Siena S Cascinu FL Rojas Llimpe C Ceccarelli V Mutri L Giannetta S Giaquinta C Funaioli R Berardi C Longobardi E Piana AA Martoni 2006 Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) Ann Oncol 18 510 517
16. P Ross M Nicolson D Cunningham J Valle M Seymour P Harper T Price H Anderson T Iveson T Hickish F Lofts A Norman 2002 Prospective randomized trial comparing mitomycin, cisplatin and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer J Clin Oncol 20 1996 2004
17. MA Shah RK Ramanathan DH Ilson A Levnor D D'Adamo E O'Reilly A Tse R Trocola L Schwartz M Capanu GK Schwartz DP Kelsen 2006 Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma J Clin Oncol 20 5201 5206
18. K Shirao Y Shimada H Kondo D Saito T Yamao H Ono T Yokoyama H Fukuda M Oka Y Watanabe A Ohtsu N Boku T Fujii Y Oda K Muro S Yoshida 1997 Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer J Clin Oncol 15 921 927
19. JR Siewert HJ Stein 1998 Classification of adenocarcinoma of the oesophagogastric junction Br J Surg 85 1457 1459
20. JA Sloan RM Goldberg DJ Sargent D Vargas-Chanes S Nair SS Cha PJ Novotny MA Poon MJ O'Connell CL Loprinzi 2002 Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer J Clin Oncol 20 1491 1498
21. A Suvannasankha C Fausel BE Juliar CT Yiannoutsos WB Fisher RH Ansari LL Wood GG Smith LD Cripe R Abonour 2007 Final reports of toxicity and efficacy of phase II study or oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: a Hoosier Oncology Group Trial, HEM01-21 Oncologist 12 99 106
22. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancers, National cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216
23. E Van Cutsem VM Moiseyenko S Tjulandin A Majlis M Constenla C Boni A Rodrigues M Fodor Y Chao E Voznyi ML Risse JA Ajani V325 Study Group 2006 Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: report of the V325 Study Group J Clin Oncol 24 4991 4997
24. U Vanhoefer P Rougier H Wilke MP Ducreux AJ Lacave E Van Cutsem M Planker JG Santos P Piedbois B Paillot H Bodenstein HJ Schmoll H Bleiberg B Nordlinger ML Couvreur B Baron JA Wils 2000 Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group J Clin Oncol 81 2648 2657
25. AD Wagner W Grothe J Haerting G Kleber A Grothey W Fleig 2006 Chemotherapy in advanced gastric cancer: systemic review and meta-analysis based on aggregate data J Clin Oncol 24 2903 2909
26. A Webb D Cunningham JH Scarffe P Harper A Norman JK Joffe M Hughes J Mansi M Findlay A Hill J Oates M Nicolson T Hickish M O'Brien T Iveson M Watson C Underhill A Wardley M Meehan 1997 Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer J Clin Oncol 15 261 267
27. JA Wils HO Klein DJ Wagener H Bleiberg H Reis F Korsten T Conroy M Fickers S Leyvraz M Buyse 1991 Sequential high-dose methotrexate and fluorouracil combined with doxorubicin-a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group J Clin Oncol 9 827 831
28. HC Zhao R Qin XX Chen X Sheng JF Wu DB Wang GH Chen 2006 Microvessel density is a prognostic marker of human gastric cancer World J Gastroenterol 21 7598 7603